Presentation is loading. Please wait.

Presentation is loading. Please wait.

Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy.

Published byAlvin Smith Modified over 8 years ago

Similar presentations

Presentation on theme: "Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy."— Presentation transcript:

1 Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy Department of Biomedical and Clinical Sciences “L. Sacco” University of Milan Milan Italy NanoBioLab Department of Biotechnology and Biosciences University of Milan-Bicocca

2 NANOMEDICINE MRI CONTRAST AGENT GENE THERAPY PHOTO-THERMAL THERAPY HYPERTHERMIA ANTIBODY-BASED THERAPY DRUG DELIVERY

3 NANO-ONCOLOGY

4 TARGETING CANCER CELLS BY SPECIFIC INTERACTION WITH HER2 HER2: Human Epidermal growth factor Receptor 2 (HER2) II. GOLD NP (KLONDY) I. IRON OXIDE NPs

5 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER FITC-TZ-magnetic nanocrystals (TMNC) Mazzucchelli S., et al. ACSNano, 2010

6 Corsi F., et al. ACSNano, 2011 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TMNC

7 5h 24h 1 w I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER Corsi F., et al. ACSNano, 2011 AF660-TMNC

8 Fiandra F., et al. ACSNano, 2013 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER FITC-magnetic nanoparticles (MNP)

9 IN VIVO TARGETING OF HER2-POSITIVE TUMORS Fiandra F., et al. ACSNano. 2013; 7; 6092-6102 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TZ/HC/scFv-MNP

10 Fiandra F., et al. ACSNano. 2013; 7; 6092-6102 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER AF660-TZ/HC/scFv-MNP

11 Corsi F., et al. ACSNano. 2011 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER IN VIVO DIAGNOSTIC POTENTIAL: INCREASE OF NEGATIVE CONTRAST Pre-injection TMNC Post-injection TMNC

12 I. IRON OXIDE NPs FOR HER-2 MEDIATED DIAGNOSIS AND THERAPY OF BREAST CANCER IN VIVO THERAPEUTIC POTENTIAL: DECREASE OF HER2 EXPRESSION NT TMNC 5h TMNC 48h TMNC 24h Corsi F., et al. ACSNano. 2011

13 II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER 2% AGAROSE GEL MONO- OR BI-FUNCTIONALIZED GOLD NP (KLONDY) Colombo M, Fiandra F., et al. Nature Communications under review

14 II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER In vitro interaction with HER2+ MCF-7 breast cancer cells Colombo M, Fiandra F., et al. Nature Communications under review 1 h, 37 °C FITC-1Tz/2Tz-NP

15 II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER Higher accumulation in tumor of 1TZ vs 2TZ-NP in vivo Mean t 1/2 (h)SD 49.937.79 45.985.90 Colombo M, Fiandra F., et al. Nature Communications under review n = 3 AF660-1TZ/2TZ-NP

16 Colombo M, Fiandra F., et al. Nature Communications under review AF660-1TZ/2TZ -NP II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER Anti-CK19

17 II. GOLD NPs FOR HER-2 MEDIATED THERAPY OF BREAST CANCER IN VIVO THERAPEUTIC EFFECT OF K1/K2-TZ VS FREE TZ 96 h sustained therapeutic effect over time only with K1-Tz Less is More !!!! Colombo M, Fiandra F., et al. Nature Communications under review

18 Acknowledgements Department of Biomedical and Clinical Sciences «L. Sacco» University of Milan Nanomedicine Laboratory «L. Sacco» University Hospital Milan NanoBioLab Department of Biotechnology and Biosciences University of Milan-Bicocca NanoMeDia Project

Download ppt "Targeted inorganic nanodevices for breast cancer diagnosis and therapy Fiandra Luisa Nanomedicine Laboratory Luigi Sacco University Hospital Milan Italy."

Similar presentations

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Nanoscale Imaging Probes for Personalized Medicine Undergraduate Researchers Leslie Chan, Rahul Balusu and Alice Chan Mentors Efstathios Karathanasis,

Nanoscale Imaging Probes for Personalized Medicine Undergraduate Researchers Leslie Chan, Rahul Balusu and Alice Chan Mentors Efstathios Karathanasis,
Nanomedicines for diagnosis and therapy. Nanomedicines.

Nanomedicines for diagnosis and therapy. Nanomedicines.
Characterization of delivery systems for nanomedicine Dr. John A. Dagata.

Characterization of delivery systems for nanomedicine Dr. John A. Dagata.
Challenges in Clinical Applications for Nanotechnology N. Tony Eissa, MD Table 3.

Challenges in Clinical Applications for Nanotechnology N. Tony Eissa, MD Table 3.
Nanomedicine and Cancer Joseph Abel Department of Physics, USU.

Nanomedicine and Cancer Joseph Abel Department of Physics, USU.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan.

Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan.
Nanoparticles and their medical applications

Nanoparticles and their medical applications
2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!

2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!
Targeted Gold Nanoparticles as Vascular Disrupting Agents during Radiation Therapy RI Berbeco 1, H Korideck 1, S Kunjachan 1, R Kumar 2, S Sridhar 2, A.

Targeted Gold Nanoparticles as Vascular Disrupting Agents during Radiation Therapy RI Berbeco 1, H Korideck 1, S Kunjachan 1, R Kumar 2, S Sridhar 2, A.
Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.
Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.
Presented By: Lana Awad and Sebastian Lukjan. Motivation of research, why they did what they did…  Understand steps that cancer cells take to spread.

Presented By: Lana Awad and Sebastian Lukjan. Motivation of research, why they did what they did…  Understand steps that cancer cells take to spread.
Bioreducible cross-linked polymer coated mesoporous silica nanoparticles for targeted delivery of siRNA to HER2+ breast cancer Nanotek & Expo, San Francisco,

Bioreducible cross-linked polymer coated mesoporous silica nanoparticles for targeted delivery of siRNA to HER2+ breast cancer Nanotek & Expo, San Francisco,
NANOMEDICINE A.A. 2011-2012. An expanding field, Nanomedicine represents an active field of pharmacological research. However, only a small part of nanodrugs.

NANOMEDICINE A.A An expanding field, Nanomedicine represents an active field of pharmacological research. However, only a small part of nanodrugs.
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.

FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Similar presentations

Ads by Google